SL Science Holding Limited (SLBT) Stock Price & Analysis
SL Science Holding Limited (SLBT) closed at USD 1.55 on Thursday, October 15, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.55; the Oct 15, 2026 session ranged USD 1.53–1.75 on volume of 130,671 shares. Market capitalization is $869.18M, with a 52-week range of USD 1.42–14.5 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SLBT.md
Key facts (SLBT)
- Analysts: None.
- Total return with dividends: 1Y -85.0% vs S&P 500 +18.1%; 5Y -84.5% vs S&P 500 +85.1%.
Analysts (SLBT)
Consensus None.
Total return (dividends reinvested) (SLBT)
| 1Y (from 2025-10-16) | 5Y (from 2025-02-03) | |
|---|---|---|
| Total return | -85.0% | -84.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -85.1% | -66.7% |
| Volatility (annualized) | 174.2% | 87.5% |
| Max drawdown | -88.2% (Feb 2026→Oct 2026) | -88.1% (Feb 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 1.55 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.55 |
| Open | USD 1.55 |
| Day Range | USD 1.53 – 1.75 |
| 52-Week Range | USD 1.42 – 14.5 |
| Volume | 130,671 shares |
| Market Cap | $869.18M |
| Exchange | NGM |
Technical Analysis (SLBT)
Nexqual's technical model rates SLBT "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.89 (neutral) |
| vs SMA50 | Below (USD 2.2) |
| MACD | -0.21 (negative) |
Analyst Ratings (SLBT)
Wall Street analysts rate SLBT "None", per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | None |
|---|
Earnings (SLBT)
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (SLBT)
| Total Revenue | $3.27M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -7.60% |
| Gross Margin | +38.41% |
| Operating Margin | -142.55% |
| Profit Margin | -72.46% |
| Debt / Equity | 0.06 |
| Current Ratio | 4.9 |
| Total Cash | $3.37M |
| Total Debt | $305,669 |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (SLBT)
Nexqual rates SL Science Holding Limited's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Weak — Revenue -8% YoY (latest Q), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $3M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$3M (TTM) |
| Efficiency | Mixed — No data |
Ownership (SLBT)
| Insider Ownership | +59.55% |
|---|---|
| Institutional Ownership | +0.29% |
| Shares Outstanding | 560.76M |
| Short % of Float | +0.02% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (SLBT)
SL Science Holding Limited is led by Ching-Dong Wang (age 53), Founder, Chairman & CEO, per Nexqual as of October 16, 2026 at 05:20 UTC.
| Founder, Chairman & CEO | Ching-Dong Wang (age 53) |
|---|---|
| CFO & Director | Ray Leung (age 43) |
| CTO & Director | Ethan Shen (age 48) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt